Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 241 entries
Sorted by: Best Match Show Resources per page
Identifying deception strategy traces: New stems of the Verifiability Approach

Theoretical frames STEM

Nahari G, Nisin Z.
GSID: rBB1IXvi_EkJ
G Nahari, Z Nisin - EAPL, Santiago De Compostela, Spain, 17th …, 2019 - researchgate.net

… Contextual attributes are imposed on the perceptual details and frame them in time and … Extending this line of strategy-based research will benefit the field both theoretically and …

Cite
Nahari, G., & Nisin, Z. (2019). Identifying deception strategy traces: New stems of the Verifiability Approach. EAPL, Santiago De Compostela, Spain, 17th–20th July.
Nahari, Galit, and Zvi Nisin. "Identifying deception strategy traces: New stems of the Verifiability Approach." EAPL, Santiago De Compostela, Spain, 17th–20th July (2019).
Copy Download .nbib Format: MLA
Psychometric properties of the Zephyr bioharness device: a systematic review.

BMC sports science, medicine & rehabilitation

Nazari G, Bobos P, MacDermid JC, Sinden KE, Richardson J, Tang A.
PMID: 29484191
BMC Sports Sci Med Rehabil. 2018 Feb 21;10:6. doi: 10.1186/s13102-018-0094-4. eCollection 2018.

BACKGROUND: Technological development and improvements in Wearable Physiological Monitoring devices, have facilitated the wireless and continuous field-based monitoring/capturing of physiologic measures in healthy, clinical or athletic populations. These devices have many applications for prevention and rehabilitation of musculoskeletal disorders,...

Cite
Nazari G, Bobos P, MacDermid JC, et al. Psychometric properties of the Zephyr bioharness device: a systematic review. BMC Sports Sci Med Rehabil. 2018;10:6doi: 10.1186/s13102-018-0094-4.
Nazari, G., Bobos, P., MacDermid, J. C., Sinden, K. E., Richardson, J., & Tang, A. (2018). Psychometric properties of the Zephyr bioharness device: a systematic review. BMC sports science, medicine & rehabilitation, 106. https://doi.org/10.1186/s13102-018-0094-4
Nazari, Goris, et al. "Psychometric properties of the Zephyr bioharness device: a systematic review." BMC sports science, medicine & rehabilitation vol. 10 (2018): 6. doi: https://doi.org/10.1186/s13102-018-0094-4
Nazari G, Bobos P, MacDermid JC, Sinden KE, Richardson J, Tang A. Psychometric properties of the Zephyr bioharness device: a systematic review. BMC Sports Sci Med Rehabil. 2018 Feb 21;10:6. doi: 10.1186/s13102-018-0094-4. eCollection 2018. PMID: 29484191; PMCID: PMC5822593.
Copy Download .nbib Format: NLM
Cerebral Wegener's granuloma: surgery mandatory for diagnosis and treatment.

Case reports in neurological medicine

Nicolosi F, Nodari G, Spena G, Roca E, Migliorati K, Esposito G, Stefini R, Fontanella M, Panciani PP.
PMID: 23762680
Case Rep Neurol Med. 2013;2013:750391. doi: 10.1155/2013/750391. Epub 2013 May 16.

The involvement of the central nervous system in case of Wegener granulomatosis (WG) is infrequent and usually leads to cranial nerve abnormalities, cerebrovascular events, and seizures. Meningeal involvement is quite rare and usually is due to the spreading from...

Cite
Nicolosi F, Nodari G, Spena G, et al. Cerebral Wegener's granuloma: surgery mandatory for diagnosis and treatment. Case Rep Neurol Med. 2013;2013:750391doi: 10.1155/2013/750391.
Nicolosi, F., Nodari, G., Spena, G., Roca, E., Migliorati, K., Esposito, G., Stefini, R., Fontanella, M., & Panciani, P. P. (2013). Cerebral Wegener's granuloma: surgery mandatory for diagnosis and treatment. Case reports in neurological medicine, 2013750391. https://doi.org/10.1155/2013/750391
Nicolosi, Federico, et al. "Cerebral Wegener's granuloma: surgery mandatory for diagnosis and treatment." Case reports in neurological medicine vol. 2013 (2013): 750391. doi: https://doi.org/10.1155/2013/750391
Nicolosi F, Nodari G, Spena G, Roca E, Migliorati K, Esposito G, Stefini R, Fontanella M, Panciani PP. Cerebral Wegener's granuloma: surgery mandatory for diagnosis and treatment. Case Rep Neurol Med. 2013;2013:750391. doi: 10.1155/2013/750391. Epub 2013 May 16. PMID: 23762680; PMCID: PMC3670469.
Copy Download .nbib Format: NLM
Maximum Time of the Effect of Antileukotriene - Zileuton in Treatment of Patients with Bronchial Asthma.

Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH

Morina N, Boçari G, Iljazi A, Hyseini K, Halac G.
PMID: 27046942
Acta Inform Med. 2016 Feb;24(1):16-9. doi: 10.5455/aim.2016.24.16-19. Epub 2016 Feb 02.

OBJECTIVE: Maximum time of the effect of antileukotriene substances - Zileuton in the treatment of patients with bronchial asthma and increased bronchial reactivity and of the salbutamol as agonist of the beta2 adrenergic receptor studied in this work.METHODS: Parameters...

Cite
Morina N, Boçari G, Iljazi A, et al. Maximum Time of the Effect of Antileukotriene - Zileuton in Treatment of Patients with Bronchial Asthma. Acta Inform Med. 2016;24(1):16-9doi: 10.5455/aim.2016.24.16-19.
Morina, N., Boçari, G., Iljazi, A., Hyseini, K., & Halac, G. (2016). Maximum Time of the Effect of Antileukotriene - Zileuton in Treatment of Patients with Bronchial Asthma. Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH, 24(1), 16-9. https://doi.org/10.5455/aim.2016.24.16-19
Morina, Naim, et al. "Maximum Time of the Effect of Antileukotriene - Zileuton in Treatment of Patients with Bronchial Asthma." Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH vol. 24,1 (2016): 16-9. doi: https://doi.org/10.5455/aim.2016.24.16-19
Morina N, Boçari G, Iljazi A, Hyseini K, Halac G. Maximum Time of the Effect of Antileukotriene - Zileuton in Treatment of Patients with Bronchial Asthma. Acta Inform Med. 2016 Feb;24(1):16-9. doi: 10.5455/aim.2016.24.16-19. Epub 2016 Feb 02. PMID: 27046942; PMCID: PMC4789724.
Copy Download .nbib Format: NLM
Molecular characterization and drug susceptibility profile of a .

Journal of medical microbiology

Armas F, Furlanello T, Camperio C, Trotta M, Novari G, Marianelli C.
PMID: 26758809
J Med Microbiol. 2016 Apr;65(4):278-285. doi: 10.1099/jmm.0.000221. Epub 2016 Jan 12.

No abstract available.

Cite
Armas F, Furlanello T, Camperio C, et al. Molecular characterization and drug susceptibility profile of a . J Med Microbiol. 2016;65(4):278-285doi: 10.1099/jmm.0.000221.
Armas, F., Furlanello, T., Camperio, C., Trotta, M., Novari, G., & Marianelli, C. (2016). Molecular characterization and drug susceptibility profile of a . Journal of medical microbiology, 65(4), 278-285. https://doi.org/10.1099/jmm.0.000221
Armas, Federica, et al. "Molecular characterization and drug susceptibility profile of a ." Journal of medical microbiology vol. 65,4 (2016): 278-285. doi: https://doi.org/10.1099/jmm.0.000221
Armas F, Furlanello T, Camperio C, Trotta M, Novari G, Marianelli C. Molecular characterization and drug susceptibility profile of a . J Med Microbiol. 2016 Apr;65(4):278-285. doi: 10.1099/jmm.0.000221. Epub 2016 Jan 12. PMID: 26758809.
Copy Download .nbib Format: NLM
[Drug-reactive diseases. I. Reactive manifestations characteristic of individual drugs].

Rivista critica di clinica medica

NOFERI G, PASCUCCI F.
PMID: 13246517
Riv Crit Clin Med. 1954 Jun 30;54(1):1-307.

No abstract available.

Cite
NOFERI G, PASCUCCI F. Le sindromi reattive da medicamenti. I. Le manifestazioni reattive proprie dei singoli farmaci. [Drug-reactive diseases. I. Reactive manifestations characteristic of individual drugs]. Riv Crit Clin Med. 1954;54(1):1-307
NOFERI, G., & PASCUCCI, F. (1954). Le sindromi reattive da medicamenti. I. Le manifestazioni reattive proprie dei singoli farmaci. [Drug-reactive diseases. I. Reactive manifestations characteristic of individual drugs]. Rivista critica di clinica medica, 54(1), 1-307.
NOFERI, G, and PASCUCCI, F. "Le sindromi reattive da medicamenti. I. Le manifestazioni reattive proprie dei singoli farmaci." [Drug-reactive diseases. I. Reactive manifestations characteristic of individual drugs]. Rivista critica di clinica medica vol. 54,1 (1954): 1-307.
NOFERI G, PASCUCCI F. Le sindromi reattive da medicamenti. I. Le manifestazioni reattive proprie dei singoli farmaci. [Drug-reactive diseases. I. Reactive manifestations characteristic of individual drugs]. Riv Crit Clin Med. 1954 Jun 30;54(1):1-307. Italian. PMID: 13246517.
Copy Download .nbib Format: NLM
beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Vassilakopoulos TP, Nadali G, Angelopoulou MK, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Karkantaris C, Kokoris SI, Dimitriadou EM, Calpadaki C, Sarantopoulos A, Galani Z, Sachanas S, Kyrtsonis MC, Tsaftaridis P, Variamis E, Panayotidis P, Pizzolo G, Sarris AH, Pangalis GA.
PMID: 17335133
J BUON. 2005 Jan-Mar;10(1):59-69.

PURPOSE: Serum beta-2 microglobulin (sbeta(2)m) is an established prognostic factor for several lymphoproliferative disorders. Because its significance in Hodgkin's lymphoma (HL) is controversial, we determined sbeta(2)m levels in pretreatment serum samples of patients with HL in order to elucidate...

Cite
Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al. beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. J BUON. 2005;10(1):59-69
Vassilakopoulos, T. P., Nadali, G., Angelopoulou, M. K., Dimopoulou, M. N., Siakantaris, M. P., Kontopidou, F. N., Karkantaris, C., Kokoris, S. I., Dimitriadou, E. M., Calpadaki, C., Sarantopoulos, A., Galani, Z., Sachanas, S., Kyrtsonis, M. C., Tsaftaridis, P., Variamis, E., Panayotidis, P., Pizzolo, G., Sarris, A. H., & Pangalis, G. A. (2005). beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 10(1), 59-69.
Vassilakopoulos, T P, et al. "beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens." Journal of B.U.ON. : official journal of the Balkan Union of Oncology vol. 10,1 (2005): 59-69.
Vassilakopoulos TP, Nadali G, Angelopoulou MK, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Karkantaris C, Kokoris SI, Dimitriadou EM, Calpadaki C, Sarantopoulos A, Galani Z, Sachanas S, Kyrtsonis MC, Tsaftaridis P, Variamis E, Panayotidis P, Pizzolo G, Sarris AH, Pangalis GA. beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. J BUON. 2005 Jan-Mar;10(1):59-69. PMID: 17335133.
Copy Download .nbib Format: NLM
Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results.

Therapeutics and clinical risk management

Metra M, Nodari S, Bordonali T, Milani P, Lombardi C, Bugatti S, Fontanella B, Verzura G, Danesi R, Dei Cas L.
PMID: 18472978
Ther Clin Risk Manag. 2007 Aug;3(4):569-78.

Clinical trials have consistently shown the benefits of beta-blocker treatment in patients with chronic heart failure (HF). As a result, bisoprolol, carvedilol, and metoprolol succinate are now indicated for the treatment of all patients with chronic HF who do...

Cite
Metra M, Nodari S, Bordonali T, et al. Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. Ther Clin Risk Manag. 2007;3(4):569-78
Metra, M., Nodari, S., Bordonali, T., Milani, P., Lombardi, C., Bugatti, S., Fontanella, B., Verzura, G., Danesi, R., & Dei Cas, L. (2007). Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. Therapeutics and clinical risk management, 3(4), 569-78.
Metra, Marco, et al. "Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results." Therapeutics and clinical risk management vol. 3,4 (2007): 569-78.
Metra M, Nodari S, Bordonali T, Milani P, Lombardi C, Bugatti S, Fontanella B, Verzura G, Danesi R, Dei Cas L. Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. Ther Clin Risk Manag. 2007 Aug;3(4):569-78. PMID: 18472978; PMCID: PMC2374926.
Copy Download .nbib Format: NLM
The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia.

Heart international

Nodari S, Rocca P, Saporetti A, Bettari L, Foresti AL, Tanghetti E, Metra M, Dei Cas L.
PMID: 21977270
Heart Int. 2007;3(1):12. doi: 10.4081/hi.2007.12. Epub 2007 Jun 15.

The combination of Simvastatin and Ezetimibe allows dual inhibition of both cholesterol production and absorption. This treatment approach allows achieving same low serum cholesterol levels with the administration of much lower doses of statins. This should reduce side effects,...

Cite
Nodari S, Rocca P, Saporetti A, et al. The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia. Heart Int. 2007;3(1):12doi: 10.4081/hi.2007.12.
Nodari, S., Rocca, P., Saporetti, A., Bettari, L., Foresti, A. L., Tanghetti, E., Metra, M., & Dei Cas, L. (2007). The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia. Heart international, 3(1), 12. https://doi.org/10.4081/hi.2007.12
Nodari, Savina, et al. "The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia." Heart international vol. 3,1 (2007): 12. doi: https://doi.org/10.4081/hi.2007.12
Nodari S, Rocca P, Saporetti A, Bettari L, Foresti AL, Tanghetti E, Metra M, Dei Cas L. The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia. Heart Int. 2007;3(1):12. doi: 10.4081/hi.2007.12. Epub 2007 Jun 15. PMID: 21977270; PMCID: PMC3184681.
Copy Download .nbib Format: NLM
Endocannabinoids and cardiovascular prevention: real progress?.

Heart international

Nodari S, Manerba A, Metra M, Dei Cas L.
PMID: 21977272
Heart Int. 2007;3(1):27. doi: 10.4081/hi.2007.27. Epub 2007 Jun 15.

The prevalence of obesity continues to increase and represents one of the principal causes of cardiovascular morbidity and mortality. After the discovery of a specific receptor of the psychoactive principle of marijuana, the cannabinoid receptors and their endogenous ligands,...

Cite
Nodari S, Manerba A, Metra M, et al. Endocannabinoids and cardiovascular prevention: real progress?. Heart Int. 2007;3(1):27doi: 10.4081/hi.2007.27.
Nodari, S., Manerba, A., Metra, M., & Dei Cas, L. (2007). Endocannabinoids and cardiovascular prevention: real progress?. Heart international, 3(1), 27. https://doi.org/10.4081/hi.2007.27
Nodari, Savina, et al. "Endocannabinoids and cardiovascular prevention: real progress?." Heart international vol. 3,1 (2007): 27. doi: https://doi.org/10.4081/hi.2007.27
Nodari S, Manerba A, Metra M, Dei Cas L. Endocannabinoids and cardiovascular prevention: real progress?. Heart Int. 2007;3(1):27. doi: 10.4081/hi.2007.27. Epub 2007 Jun 15. PMID: 21977272; PMCID: PMC3184683.
Copy Download .nbib Format: NLM
Interaction of NO with nanosized Ru-, Pd-, and Pt-Doped SnO2: electron paramagnetic resonance, Mössbauer, and electrical investigation.

The journal of physical chemistry. B

Canevali C, Mari CM, Mattoni M, Morazzoni F, Nodari L, Ruffo R, Russo U, Scotti R.
PMID: 16851821
J Phys Chem B. 2005 Apr 21;109(15):7195-202. doi: 10.1021/jp040740k.

The mechanism of NO interaction with nanosized Ru(Pd,Pt)-doped SnO(2) was studied by electron paramagnetic resonance, Mössbauer, and electric resistance measurements. Three steps were proposed for the reaction between the semiconductor oxide and the gaseous component: (i) the formation of...

Cite
Canevali C, Mari CM, Mattoni M, et al. Interaction of NO with nanosized Ru-, Pd-, and Pt-Doped SnO2: electron paramagnetic resonance, Mössbauer, and electrical investigation. J Phys Chem B. 2005;109(15):7195-202doi: 10.1021/jp040740k.
Canevali, C., Mari, C. M., Mattoni, M., Morazzoni, F., Nodari, L., Ruffo, R., Russo, U., & Scotti, R. (2005). Interaction of NO with nanosized Ru-, Pd-, and Pt-Doped SnO2: electron paramagnetic resonance, Mössbauer, and electrical investigation. The journal of physical chemistry. B, 109(15), 7195-202. https://doi.org/10.1021/jp040740k
Canevali, Carmen, et al. "Interaction of NO with nanosized Ru-, Pd-, and Pt-Doped SnO2: electron paramagnetic resonance, Mössbauer, and electrical investigation." The journal of physical chemistry. B vol. 109,15 (2005): 7195-202. doi: https://doi.org/10.1021/jp040740k
Canevali C, Mari CM, Mattoni M, Morazzoni F, Nodari L, Ruffo R, Russo U, Scotti R. Interaction of NO with nanosized Ru-, Pd-, and Pt-Doped SnO2: electron paramagnetic resonance, Mössbauer, and electrical investigation. J Phys Chem B. 2005 Apr 21;109(15):7195-202. doi: 10.1021/jp040740k. PMID: 16851821.
Copy Download .nbib Format: NLM
Impacts of fresh lime juice and peel on atherosclerosis progression in an animal model.

ARYA atherosclerosis

Boshtam M, Asgary S, Moshtaghian J, Naderi G, Jafari-Dinani N.
PMID: 24575139
ARYA Atheroscler. 2013 Nov;9(6):357-62.

BACKGROUND: The main protective role of antioxidants in the progression of atherosclerosis has been shown in some studies. Therefore, this project evaluated the effects of Citrus aurantifolia (Christm) juice and peel on antioxidant activity and atherosclerosis progression in rabbits...

Cite
Boshtam M, Asgary S, Moshtaghian J, et al. Impacts of fresh lime juice and peel on atherosclerosis progression in an animal model. ARYA Atheroscler. 2013;9(6):357-62
Boshtam, M., Asgary, S., Moshtaghian, J., Naderi, G., & Jafari-Dinani, N. (2013). Impacts of fresh lime juice and peel on atherosclerosis progression in an animal model. ARYA atherosclerosis, 9(6), 357-62.
Boshtam, Maryam, et al. "Impacts of fresh lime juice and peel on atherosclerosis progression in an animal model." ARYA atherosclerosis vol. 9,6 (2013): 357-62.
Boshtam M, Asgary S, Moshtaghian J, Naderi G, Jafari-Dinani N. Impacts of fresh lime juice and peel on atherosclerosis progression in an animal model. ARYA Atheroscler. 2013 Nov;9(6):357-62. PMID: 24575139; PMCID: PMC3933061.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 241 entries